Investment Rating - The report initiates coverage with a "Buy" rating for Shanghai Pharmaceuticals [2][5]. Core Views - Shanghai Pharmaceuticals is positioned to leverage both distribution and industrial segments, enhancing its innovative value across the entire industry chain [4]. - The company is actively embracing new business models to address the overall profit compression in the pharmaceutical distribution industry and increasing competition [5]. - The report forecasts significant revenue and profit growth for the company from 2025 to 2027, with expected revenues of RMB 302.3 billion, RMB 333.3 billion, and RMB 366.3 billion, respectively, and corresponding net profits of RMB 5.3 billion, RMB 6.2 billion, and RMB 7.1 billion [4][5]. Company Overview - Shanghai Pharmaceuticals, established in 1952, has evolved into a comprehensive pharmaceutical enterprise covering manufacturing, distribution, and traditional Chinese medicine [4][14]. - The company became the first A+H listed pharmaceutical company in China and has undergone significant transformations, including the introduction of Yunnan Baiyao as a major shareholder [4][15]. Financial Data and Profit Forecast - The company is projected to achieve revenues of RMB 260.3 billion in 2023, with a year-on-year growth rate of 12.21%, and a net profit of RMB 3.8 billion, reflecting a decline of 32.92% [3][25]. - For 2024, revenues are expected to reach RMB 275.3 billion, with a net profit of RMB 4.6 billion, indicating a growth of 20.82% [3][25]. - The report anticipates a steady increase in revenue and profit margins, with a focus on innovative drug development and operational efficiency [4][5]. Distribution Business - The pharmaceutical distribution market in China is approximately RMB 3 trillion, with a significant portion attributed to wholesale [38]. - Shanghai Pharmaceuticals ranks second among national pharmaceutical wholesalers, benefiting from the industry's increasing concentration and digital transformation [47]. - The company is enhancing its distribution network and operational efficiency through strategic integration and innovative business models [49][60]. Pharmaceutical Manufacturing - The industrial segment of Shanghai Pharmaceuticals includes a diverse range of products, such as generic drugs, innovative drugs, and traditional Chinese medicine [67]. - The company has established production bases across 12 provinces and cities in China and overseas, producing around 800 varieties of drugs [67]. - The report highlights the company's commitment to increasing research and development investments, particularly in innovative drug pipelines [4][5]. Growth Highlights - The company is focusing on building a comprehensive lifecycle service platform for innovative drugs, which has shown significant sales growth [54]. - Shanghai Pharmaceuticals is implementing the SPD model to enhance supply chain management for medical institutions, which has led to increased sales in medical devices [56]. - The "1+1+1" model in Shanghai is being leveraged to improve grassroots medical efficiency, providing significant growth opportunities for the company's distribution business [61][66].

Meeting Details - The shareholders' meeting was held on June 25, 2025, at the company's headquarters in Guangzhou [1] - The attendance rate of ordinary shareholders and preferred shareholders with restored voting rights was 76.7419% [1] - The meeting was convened by the board of directors and presided over by director Ke Guoqiang, following legal and procedural requirements [1] Voting Results - All non-cumulative voting proposals were approved, with 99.2431% of A-shareholders voting in favor [1] - The voting breakdown showed 862,239,871 votes in favor, 6,475,995 against, and 99,424 abstentions [1] Legal Compliance - The lawyers confirmed that the meeting's procedures complied with relevant laws and regulations, ensuring the legality of the attendees and the voting process [2]

| | | A股董秘学历分布及对比 | | | | --- | --- | --- | --- | --- | | | 杰出董秘 | | 全部A股 | | | 学历 | 人数(人) | 足比 | 人数(人) | 早比 | | 高中及以下 | 1 | 0.40% | 21 | 0.39% | | 大专及本科 | 90 | 36.00% | 2638 | 48.60% | | 硕士及以上 | 156 | 62.40% | 2694 | 49.63% | 在资本市场的舞台上，董秘扮演着至关重要的角色。他们不仅是上市公司与投资者之间的桥梁，更是公 司价值传播、投资者沟通与公司治理的关键角色。 高水准传播公司价值 合规、透明的信息披露是上市公司董秘的重要工作之一，是向投资者传递公司价值的重要途径。杰出董 秘在信息披露合规性方面表现出色，250位董秘的信披评级均为"A"或"B"，其中112位董秘获得了最高 的"A级"评级，占比接近一半。这一比例充分体现了获奖董秘在信息披露工作中的卓越表现和专业能 力。 证券时报社主办的"中国上市公司投资者关系管理天马奖"活动迄今已举办16届，持续关注董秘这一职业 群体的发展现状及特点。近 ...

Core Viewpoint - Nanjing Pharmaceutical (600713) plans to lease a property located at 27 Yanling Lane, Qinhuai District, Nanjing through a public listing, with an estimated first-year rental value of 7.1155 million yuan based on the assessment date [1] Summary by Relevant Sections - **Property Details** - The total area of the property is 13,325.11 square meters [1] - The lease term is set for 13 years (156 months), with a 6-month rent-free period [1] - **Financial Projections** - Rent will be paid quarterly, with the rental price remaining unchanged for the first three years [1] - Starting from the fourth year, the rent will increase by 5% every three years based on the previous year's rent [1] - The total expected rental income over the 13-year lease period is approximately 97.0973 million yuan [1] - **Transaction Process** - The final transaction price and the lessee will be determined based on the results of the public listing [1]

Summary of Key Points Core Viewpoint - The announcement details the progress of external guarantees provided by Kunming Pharmaceutical Group Co., Ltd. to its subsidiaries, emphasizing the financial support for their operational needs in 2025 and the associated risks due to high debt levels of the guaranteed companies [1][6]. Group 1: Guarantee Details - The total guarantee amount provided to the subsidiaries is RMB 12.5 million, with a cumulative guarantee balance of RMB 33.7 million [1]. - The guaranteed companies, Qujing Kangqiao Pharmaceutical Co., Ltd. and Kunming Commercial (Zhaotong) Pharmaceutical Co., Ltd., are both subsidiaries of Kunming Pharmaceutical Group [1][2]. - There are no collateral guarantees associated with this external guarantee [1]. Group 2: Financial Status of Guaranteed Companies - Qujing Kangqiao has an asset-liability ratio of 73.60% as of March 31, 2025, indicating a high level of debt [2]. - Kunming Commercial (Zhaotong) has an asset-liability ratio of 86.07% as of March 31, 2025, also reflecting significant financial leverage [2]. - Both companies are not classified as dishonest executors, and their credit status is reported as good [2]. Group 3: Board of Directors' Opinion - The board believes that the guarantees are necessary to support the subsidiaries' operational needs, enhance financing efficiency, and lower financing costs [6]. - The board has assessed the financial stability and operational conditions of the guaranteed companies, concluding that the overall risk is manageable [6]. Group 4: Cumulative Guarantee Information - As of the announcement date, the total external guarantee balance of the company and its subsidiaries is RMB 113.85 million, which is 2.17% of the latest audited net assets [7]. - The total guarantee amount provided to subsidiaries is RMB 456.15 million, representing 8.68% of the latest audited net assets [7].

Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is issuing convertible bonds to unspecified investors, with a total amount of RMB 1,081,491,000, to be used for various investment projects [3][16][18]. Group 1: Issuance Details - The company has received approval from its board and regulatory authorities for the issuance of 10,814,910 convertible bonds, each with a face value of RMB 100 [3][4]. - The net proceeds from the issuance amount to RMB 1,069,040,922.31, which has been verified by KPMG Huazhen [3][18]. - The bonds will have a maturity period of six years from the issuance date, with an annual interest rate starting at 0.20% in the first year [5][12]. Group 2: Bond Terms - The initial conversion price for the bonds is set at RMB 5.29 per share, subject to adjustments based on corporate actions such as stock dividends and capital increases [8][21]. - The company has the right to redeem the bonds at 108% of the face value after five trading days post-maturity if certain conditions are met [9][10]. - Holders of the bonds can sell them back to the company at face value plus accrued interest if the stock price falls below 70% of the conversion price during the last two interest years [10][11]. Group 3: Use of Proceeds - The total investment amount for the projects funded by the bond proceeds is RMB 118,665,520, with the shortfall to be covered by the company’s own funds [16][18]. - The company plans to allocate the raised funds to specific projects, ensuring that the actual net proceeds are utilized effectively [16][18]. Group 4: Shareholder Rights - Original shareholders will have priority in subscribing to the bonds based on their holdings as of the record date, with specific timelines for subscription and payment [14][16]. - The company will ensure that the rights of bondholders are protected and that any adjustments to the conversion price are communicated transparently [20][22].

债券代码：110098 债券简称：南药转债 证券代码：600713 证券简称：南京医药 编号：ls2025-091 南京医药股份有限公司 关于因实施权益分派调整可转债转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 调整前转股价格：5.29 元/股 ? 调整后转股价格：5.12 元/股 ? "南药转债"本次转股价格调整实施日期：2025 年 6 月 30 日 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可【2024】1736 号）， 核准南京医药股份有限公司（以下简称"公司"）本次可转换公司债券（以下简称"可 转债"）发行。公司向不特定对象发行可转债 10,814,910 张，每张面值为人民币 100 元，并于 2025 年 1 月 20 日在上海证券交易所上市交易（债券简称：南药转债，债券 代码：110098），初始转股价格为 5.29 元/股。 一、转股价格调整依据 公司股份回购专用证券账户持有股数）为基数分配利润，向全体股东每 10 股派发现金 红利 1.70 元（含税）。在 ...

中国医药（600056）公告，公司收到参股公司重庆医健股东重庆渝富拟公开挂牌转让重庆医健24%股权 的通知，股权转让底价为22.06亿元。公司决定放弃该股权的优先购买权。本次放弃优先购买权事项尚 无法确定是否构成关联交易，不构成重大资产重组情形。公司第九届董事会第28次会议审议通过该议 案，尚需提交股东大会审议。本次放弃优先购买权不会导致公司合并报表范围发生变化，亦不会导致公 司对重庆医健的持股比例下降，不存在损害公司及股东利益的情形，不会对公司财务及经营状况产生重 大影响。 ...

北京市竞天公诚律师事务所上海分所 关于 南京医药股份有限公司 差异化分红 法律意见书 上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 Suite 45/F, K.Wah Centre, 1010 Huaihai Road (M), Xuhui District, Shanghai 200031, China 电话/Tel: +86 21 5404 9930 传真/Fax: +86 21 5404 9931 网址/Website: http://www.jingtian.com 二〇二五年六月 北京市竞天公诚律师事务所上海分所 法律意见书 北京市竞天公诚律师事务所上海分所 关于南京医药股份有限公司 差异化分红之法律意见书 致：南京医药股份有限公司 根据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国 证券法》 （以下简称"《证券法》"）、 《上市公司股份回购规则》 （以下简称"《回购 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则（试 行）》等规定以及在本法律意见书出具日之前已经发生或存在的事实出具法律意 见。本所已经严格履行了法定职责，遵 ...

通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有 资金或自筹资金通过集中竞价交易方式回购公司股份，用于实施 2025 年限制性 股票激励计划。截至 2025 年 4 月 30 日，公司通过集中竞价交易方式已累计回购 公司股份 16,299,951 股。 议审议通过了《关于向公司 2025 年限制性股票激励计划激励对象首次授予限制 性股票的议案》，同意公司向 173 名激励对象首次授予 16,059,000 股限制性股票。 在资金缴纳过程中，有 1 名激励对象放弃认购，涉及股数 40,000 股，因此本次 激励计划首次授予激励对象人数由 173 人调整为 172 人，首次授予股数由 性股票激励计划首次授予登记工作。本次授予完成后，公司回购专用证券账户 （B887180567）中剩余 280,951 股无限售流通股。 根据《公司法》《证券法》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关法律、法规及规范性文件的规定，公司回购专用账户持 有的公司股份不参与利润分配。因此，公司 2024 年度权益分配实施差异化分红。 二、股东大会审议通过的差异化权益分派方案 中信建投证券股份 ...